ACTA1 and Hepatic fibrosis: Additionally, M2-BMDM-EV treatment markedly inhibited cell apoptosis and suppressed the expression of liver fibrosis markers, including α-SMA and collagen type I alpha 1 (Col1a1) (Fig. 1F).